A medical device designed by a UH professor will close the loop with high frequency brain waves to prevent seizures from occurring. Photo via uh.edu

A professor at the University of Houston has received a federal grant aimed at helping stop epileptic seizures before they start.

The BRAIN Initiative at the National Institute of Neurological Disorders and Stroke awarded the $3.7 million grant to Nuri Firat Ince, an associate professor of biomedical engineering at UH. The grant will go toward Ince's work to create a seizure-halting device based on his research.

According to UH, Ince has reduced by weeks the time it takes to locate the seizure onset zone (SOZ), the part of the brain that causes seizures in patients with epilepsy. He's done this by detecting high-frequency oscillations (HFO) forming "repetitive waveform patterns" that identify their location in the SOZ.

Ince plans to use those HFOs to help control seizures. But he first must determine whether the HFOs can be detected with an implantable closed-loop device, enabling delivery of electrical stimulation that can control seizures. The device is called a brain interchange system. A closed-loop system supplies stimulation only when it detects the onset of a seizure.

Ince's neurotechnology partner, Cortec GMBH of Freiburg, Germany, is supplying the brain interchange system. Houston's Baylor College of Medicine eventually will be the site where medical professionals implant the device in pediatric and adult epilepsy patients.

"If the outcomes of our research in acute settings become successful, we will execute a clinical trial and run our methods with the implanted … system in a chronic ambulatory setting," Ince says in a UH news release.

Research published recently in the journal AJOB Neuroscience found that a closed-loop brain implant being used to treat refractory epilepsy does not alter patients' personalities or self-perception.

Nuri Firat Ince associate professor of biomedical engineering. Photo via uh.edu

"Next-generation brain stimulation devices can modulate brain activity without human intervention, which raises new ethical and policy questions," lead author Tobias Haeusermann of the University of California, San Francisco, says in a news release. "But while there is a great deal of speculation about the potential consequences of these innovative treatments, very little is currently known about patients' experiences of any device approved for clinical use."

The study, however, found no evidence that the device Haeusermann and his colleagues studied had changed patients' personalities or self-perception.

Haeusermann and his fellow researchers based their study on a closed-loop device that's currently available. In 2013, the U.S. Food and Drug Administration (FDA) approved this brain stimulation system for treatment of refractory epilepsy. It's the first clinically approved and commercially available closed-loop brain stimulation device for epilepsy patients. Refractory epilepsy occurs when medication no longer controls seizures.

According to a research article published in 2018, epilepsy ranks among the most common neurological disorders, affecting about 1% of the global population. For patients who suffer seizures that cannot be treated with drugs, a frequent treatment is surgical removal of the SOZ.

In this country, about 3 million adults and 470,000 children have epilepsy, according to the U.S. Centers for Disease Control and Prevention, including nearly 293,000 Texans. In the U.S., epilepsy is the fourth most common neurological disorder, preceded by migraine, stroke and Alzheimer's disease, the Epilepsy Foundation of Michigan says.

About 150,000 Americans are diagnosed each year with epilepsy.

Epilepsy is prevalent among people with autism, cerebral palsy, Down syndrome, and intellectual disabilities.

About 30 types of seizure occur among the more than 60 types of epilepsy, the Michigan foundation says. A seizure briefly disturbs electrical activity in the braining, causing temporary changes in movement, awareness, feelings, behavior, and other bodily functions.

Daily medication is the standard treatment for epilepsy, according to the Michigan foundation. Still, 30 percent to 40 percent of people with epilepsy continue to experience seizures.

Each year, U.S. health care costs associated with epilepsy add up to roughly $28 billion, according to the American Journal of Managed Care.

"Most people with epilepsy are able to lead productive and fulfilling lives, but for many, epilepsy can be a devastating condition," the foundation says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston edtech company closes oversubscribed $3M seed round

fresh funding

Houston-based edtech company TrueLeap Inc. closed an oversubscribed seed round last month.

The $3.3 million round was led by Joe Swinbank Family Limited Partnership, a venture capital firm based in Houston. Gamper Ventures, another Houston firm, also participated with additional strategic partners.

TrueLeap reports that the funding will support the large-scale rollout of its "edge AI, integrated learning systems and last-mile broadband across underserved communities."

“The last mile is where most digital transformation efforts break down,” Sandip Bordoloi, CEO and president of TrueLeap, said in a news release. “TrueLeap was built to operate where bandwidth is limited, power is unreliable, and institutions need real systems—not pilots. This round allows us to scale infrastructure that actually works on the ground.”

True Leap works to address the digital divide in education through its AI-powered education, workforce systems and digital services that are designed for underserved and low-connectivity communities.

The company has created infrastructure in Africa, India and rural America. Just this week, it announced an agreement with the City of Kinshasa in the Democratic Republic of Congo to deploy a digital twin platform for its public education system that will allow provincial leaders to manage enrollment, staffing, infrastructure and performance with live data.

“What sets TrueLeap apart is their infrastructure mindset,” Joe Swinbank, General Partner at Joe Swinbank Family Limited Partnership, added in the news release. “They are building the physical and digital rails that allow entire ecosystems to function. The convergence of edge compute, connectivity, and services makes this a compelling global infrastructure opportunity.”

TrueLeap was founded by Bordoloi and Sunny Zhang and developed out of Born Global Ventures, a Houston venture studio focused on advancing immigrant-founded technology. It closed an oversubscribed pre-seed in 2024.

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.